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Greater Trochanteric Pain syndrome (GTPS) is a debilitating condition causing lateral hip pain 
(Grimaldi & Fearon, 2015). It affects up to 23.5% of women and 8% of men between 50-75 years old 
(Segal et al., 2007). Existing data suggests that patients with GTPS report difficulty sleeping; and 
moderate to severe pain and disability, and comparable quality of life to people with advanced 
osteoarthritis of the hip (Fearon et al., 2013; Fearon et al., 2014). Originally considered an 
inflammatory condition of the trochanteric bursa; recent imaging, surgical and histology studies 
have suggested it to be, most commonly, a condition associated with tendinopathy of the gluteus 
medius and minimus tendons at the site of their insertion onto the greater tuberosity of the femur 
(Fearon et al., 2010; Long, Surrey & Nazarian, 2013). 
A recent randomised controlled trial (LEAP trial) reported 78.5% success rates on the global rating of 
change scale with education and exercise interventions for patients with GTPS (Mellor et al., 2018).  
These outcomes were superior to cortico-steroid injection (58.3%) and wait and see (51.9%) 
approaches at 12-months post intervention (Mellor et al., 2018). However, the patients recruited to 
this study were community dwellers and not patients seeking healthcare interventions. Patients 
were also excluded if they had advanced osteoarthritis of the hip (>2 Kellgren Lawrence scale) or 
knee, low back pain (>2/10), systemic inflammatory diseases, or systemic diseases affecting the 
muscular or nervous system (Mellor et al, 2016). Current data suggests that patients with GTPS are 
often overweight, and complain of low back pain, osteoarthritis of the spine or ipsilateral hip or knee 
(Segal et al., 2007). GTPS is more common in post-menopausal women, and has also been shown to 
be highly prevalent in patients awaiting renal transplant (Demant et al., 2007; Lievense et al., 2015). 
The extent to which co-morbidities are present, and the impact of them in patients with GTPS is 
unknown, yet cardiovascular, hormonal and endocrine disorders are known risk factors for 
developing other lower limb tendinopathies (Abate, Schiavone, Salini & Andia, 2013).    
Age, gender, family support, severity of symptoms, greater healthcare needs due to chronic 
conditions, and beliefs about disease and ability of healthcare to change it, are all factors which 
influence healthcare seeking behaviour (Cornally & McCarthy, 2011; Thompson et al., 2016;). Many 
of these factors are also risk factors for musculoskeletal pain (Artus et al., 2017; Linton & Shaw, 
2011; Valentin et al., 2016).  
Little is known about the characteristics of patients with GTPS who present to physiotherapy 
services within the National Health Service (NHS). Given the range of risk and prognostic factors 
associated with GTPS, it is important to understand these characteristics to enable consideration of 
the applicability of the findings of the LEAP trial to typical NHS patients. Hence the primary aim of 
this multi-site service evaluation was to collect and synthesise data on the characteristics of patients 
with a primary complaint of GTPS, presenting to the NHS. As a secondary aim, the characteristics of 
these NHS patients will then be compared with the participants recruited to the LEAP trial, to 
















Recruitment and data analysis 
Four eligible NHS sites from the United Kingdom (UK) responded to a request via Twitter to share 
anonymised data. The request was aimed at clinicians working within NHS physiotherapy services 
who had collected data and outcome measures for patients presenting with a primary complaint of 
GTPS, as part of their routine care over the previous twelve-month period. The request explained 
the aim of the data collection was to characterise the typical patient who presents to the NHS with 
GTPS. Examples of the type of information required (age, gender, medical history, duration and 
distribution of symptoms) was explained in the initial request. Individuals who responded to the 
request were sent the data capture excel spreadsheet (Appendix 1) to enable them to complete 
local governance approval prior to sharing any data.  
The participating sites were made up of two Clinical Musculoskeletal Assessment and Treatment 
Services (CMATS), one General Hospital and one elective Orthopaedic Hospital. Each site was asked 
to randomly select approximately 40 patients that had been seen within their service between April 
2017 and April 2018, presenting for treatments of lateral hip pain and given a clinical diagnosis of 
GTPS by the treating physiotherapist in either Consultant led, or physiotherapy out-patient clinics. A 
clinical diagnosis was accepted for inclusion as clinical testing for GTPS has a high diagnostic validity 
and physiotherapists in the UK appear confident with a clinical diagnosis for the condition 
(Ganderton et al., 2017; Stephens et al., 2019). Three sites chose the first forty patients for the given 
time period who fitted the criteria; whilst one site identified eligible patients at random. The only 
inclusion criteria applied was a diagnosis of GTPS by the treating clinician, to ensure the sample most 
accurately reflected the patient who seeks care in the NHS. The domains identified for inclusion in 
the data capture tool were pre- determined by the lead author (GS) and two co-authors (CL, SON). 
Sites were informed that the anonymised data would be used to define the characteristics of 
patients with GTPS, attending the NHS. 
Medical conditions were classified using the World Health Organisation, International Classification 
of Diseases 11th Revision (World Health Organisation, 2018) and medications were categorised using 
the British Medical Association, New guide to Medicine and Drugs, 9th Edition (2015). 
Data were analysed descriptively using means, standard deviations and percentages, where relevant. 
Comparisons of the mean values to the LEAP trial were conducted using t-test for interval and ratio 
data and chi-squared analysis of categorical data. 
 
Ethical Approval 
Service evaluation, is a process which is used solely to define or judge current care, without 
reference to a standard (NHS Health Research Authority, 2016). This evaluation defined current care 
but focussed particularly on the characteristics of patients accessing physiotherapy services. This 
evaluation collated retrospective data, collected as part of routine clinical practice which had been 
completely anonymised at site before sharing. It therefore fulfilled criteria of a multi-site service 








3.1 Patient characteristics 
Overall, data on 162 subjects was collected and synthesised. The majority of patients were female 
(118/162; 73%), with an average age of 59 years of age, presenting with unilateral lateral hip pain 
(148/162; 91.4%) of more than 12-months in duration (92/162; 56.8%).  
 BMI data was obtained on 22.2% of subjects; of those the mean BMI was 28.4; and therefore, 














Table 1. Characteristics and presenting condition. 
Characteristic No. of 
subjects 
(% of subjects) 
Mean 
(SD) 
LEAP No. of 
subjects 



















































































































Lying / Sleeping 
Standing (including sit to stand) 
Sitting / driving 
Stairs 









































3.2 Patient presentations 
All patients presented with a primary complaint of lateral hip pain. Referred symptoms were 
common, as 30.2% of patients reported experiencing pain radiating to the lateral thigh (49/162). 
Associated lower back pain (LBP) was reported by 21.0% (34/162). Co-existing buttock pain / 
posterior hip (25/162; 15.4%); groin / anterior thigh pain (24/162; 14.9%); ipsilateral knee pain 
(14/162; 8.6%) and pain below the knee (12/162; 7.4%) were also reported (Fig 1). 





Patients with GTPS commonly reported problems with walking (106/162: 65.4%), lying / sleeping 
(98/162; 60.5%), standing (79/162; 48.8%) and sitting / driving (39/162; 24.1%).  Subjects reported 
average pain scores of 6.5 (on a numerical rating scale out of 10) and health related quality of life 






















Table 2. Medical History of subjects. 
 No. of 
subjects 








Lower limb osteoarthritis 
Lower limb arthroplasty 
Low back pain 


























Cardiovascular 49 30.2% 60 17.1% 
Digestion 31 19.1% 34 9.7% 
Metabolic/ endocrine 29 17.9% 32 9.1% 
Respiratory 20 12.3% 21 6.0% 
Neoplasms 19 11.7% 21 6.0% 
Nervous system 16 9.8% 16 4.6% 
Mental Health 15 9.3% 17 4.9% 
Gastro-intestinal 15 9.3% 16 4.6% 
Blood 5 3.1% 5 1.4% 
Visual 5 3.1% 7 2.0% 
Ear 4 2.5% 4 1.1% 














One hundred and twenty-eight (79.0%) subjects reported suffering from 350 health complaints, 
other than lateral hip pain (Table 2). 56.8% (92/162) of subjects reported more than one health 
complaint and within that group, 14.1% (23/162) had four or more co-existing medical conditions. 
The most common complaints reported by subjects were musculoskeletal (71/162; 43.8%), 
cardiovascular (49/162; 30.2%), digestion (31/162; 19.1%) and metabolic / endocrine complaints 
(29/162; 17.9%). The 71 subjects, who reported co-existing musculoskeletal problems, reported 108 
musculoskeletal complaints. Most commonly lower limb osteoarthritis (25/162; 15.4%), previous 
lower limb arthroplasty (19/162; 11.7%) and low back pain (19/162; 11.7%).  
459 prescribed medications were taken by 134 (82.7%) subjects; with analgesics being the most 
commonly prescribed drug (Table 3). Opioid based analgesics (35.2%), non-opioid based analgesics 
(34.0%) and non-steroidal anti-inflammatory analgesics (23.4%) were the most commonly prescribed 
medications. The 108 subjects who were taking medication affecting the central nervous system; 
were taking 150 prescriptions of analgesics. On top of this a further 15 prescriptions of Tri-cyclic anti-
depressants (such as Amitriptyline), and anti-convulsant medication (such as Gabapentyn) were 
taken by subjects. These medications are commonly prescribed for the management of persistent 
pain.  
Other than analgesia; medications affecting the cardiovascular system (54/162; 34.9%) and hormone 









Table 3 Medication taken by subjects. 














































Angiotensin 2 blockers 
Ace inhibitors 
Calcium channel blockers 


































Hormone and endocrine system 
Diabetes altering medication 
Hypo-thyroid medication 

























































































































The majority of patients (101/162; 62.3%) had undergone radiological investigations for their lateral 
hip pain as part of this or a previous episode of care, with almost 10% (15/162; 9.3%) having more 
than one investigation. X-ray (71/162; 44.3%) was the most commonly performed investigation, 
followed by MRI scan (32/162; 19.8%) and ultrasound scan (11/162; 6.8%). 
At the point of assessment for the examined episode of treatment, 40.7% (66/162) of subjects had 
received previous treatment for lateral hip pain, most commonly physiotherapy (45/192; 23.4%) and 
corticosteroid injection (31/162; 19.1%). 10.5% (17/162) of subjects had received more than one 
type of intervention, and 8.6% (14/162) had received more than one corticosteroid injection. 
As part of the examined episode of care, subjects underwent an average of 4.6 (SD 3.0) treatment 
sessions. The majority of physiotherapists treated subjects with strengthening / loading exercises 
(149/162; 92.0%) and education (77/162; 47.5%); whilst 12.0% (23/162; 14.2%) underwent 
corticosteroid injection.  
Clinical outcome data in terms of a numerical rating scale (0-10 or 0-100), was available in 50.6% 
(82/162) of cases. Patients scoring 0, were deemed to have had ‘no improvement’, patients 
providing the maximum score were deemed to be ‘completely resolved’ and subjects who provided 
any scores in between these values, were categorised as having received ‘some benefit’ from 
treatment. In two cases (2/82; 2.4%), no numerical rating was provided, instead, it was described 
that the individual’s symptoms had worsened with treatment. The majority demonstrated some 
improvement (48/82; 58.5%); with similar numbers experiencing no improvement (15/82; 18.3%) as 





The data from this service evaluation suggests that patients presenting to Physiotherapy services 
within the NHS with a primary complaint of GTPS have different characteristics than participants 
recruited to the LEAP trial. Comparisons suggest they are older (4.6 years), report higher levels of 
pain (VAS 1.5), have a higher BMI, and report lower health related quality of life (EQ5D Index 0.1). 
Two recent systematic reviews reporting risk factors of persistent, non-malignant pain, suggest that 
these findings might be important, as people with musculoskeletal conditions who report higher 
levels of pain and disability at the outset, report poorer clinical outcomes (Artus et al., 2017; 
Valentin et al., 2016). One of the reviews also reported older age as an important prognostic factor 
(Valentin et al., 2016). Research looking at other lower limb tendinopathies suggests that the 
incidence is higher in older age groups, however age is not necessarily a causative factor (Longo et 
al., 2009; Maffuli & Kader, 2002). High body mass index (BMI) has not been demonstrated to be a 
significant prognostic indicator of persistent pain or tendinopathy, however this has not been 
examined in large cross-sectional studies of patients with GTPS (Artus et al., 2017; Fearon et al., 
2012; Lievense et al., 2005; Valentin et al., 2016). Patients with GTPS have been demonstrated to 
have higher central adiposity than asymptomatic age matches controls; a finding which has been 
identified as a risk factor for the development of other tendinopathies (Fearon et al., 2012; Gaida, 
Ashe, Bass & Cook, 2009; Scott et al., 2015). The typical patient presenting to physiotherapy services 
in the NHS with GTPS had a higher BMI than the community dwellers recruited to the LEAP trial. 
Data from this and other studies suggests that the majority of patients with GTPS are ‘overweight’ 
according to their BMI (Mellor et al., 2018; Woodley et al., 2008). 
This service evaluation suggests that a number of patients presenting to physiotherapy services in 
the NHS with GTPS experience referral of symptoms into the lateral thigh (30.2%), lumbar spine 
(21.0%), buttock (15.4%) and groin (14.9%). This is not a surprise given that so many patients 
experience pain lasting more than 12-months (56.8%) and the central nervous system adaptions 
which occur with persistent pain (Vardeh et al., 2017).  The co-existence of LBP and GTPS is well 
established, although not well understood or researched, as patients with LBP are often excluded 
from trials (Tan et al., 2018; Tortolani, Carbone, & Quartararo, 2012). In this evaluation, 11.7% of 
patients suffered persistent LBP and 21.0%, suggested that they experienced back pain alongside 
their lateral hip pain. In a study of 40 patients seeking healthcare with GTPS; 30% experienced co-
existing low back pain and 75% had experienced an episode of low back pain in the previous 2 years 
(Woodley et al, 2008). Patients were excluded from the LEAP trial if they experienced more than 
2/10 pain on lumbar spine flexion (Mellor et al., 2016); suggesting that there may be an important 
group of patients seen in the NHS that were excluded from the LEAP trial.  
Nearly half (43.8%) of the patients with GTPS in this service evaluation were also likely to have other 
musculoskeletal pain problems, including previous arthroplasty (11.7%) and lower limb 
osteoarthritis (15.4%). Patients with groin pain (>2/10 average intensity over a week) or reduced hip 
range of motion (<90 degrees flexion) were excluded from the LEAP trial as symptoms from 
osteoarthritis can often mimic GTPS (Mellor et al., 2016). Our data suggests that groin pain (14.9%) 
and osteoarthritis of the lower limb (15.4%) appear to co-exist with GTPS in a number of cases; a 
finding supported by other research (Albers, Zwerver, Diercks, Dekker, & Van Der Akker-Scheek, 
2016; Lievense et al., 2005; Segal et al., 2007). This may be significant as Lievense et al, (2005), found 
that patients with co-existing GTPS and lower limb OA, were almost five times (x4.77) more likely to 
have symptoms persisting at twelve months.  Lower extremity OA appears to co-exist with GTPS in a 
substantial proportion of patients, and research is required to ascertain how current rehabilitative 
strategies affect this specific sub-group.  
71 subjects in this service evaluation reported 108 different musculoskeletal pain problems. The 
data in this evaluation on the prevalence of referred symptoms and co-existing musculoskeletal pain 
problems is significant, as widespread pain has been established a predictor of longer term 
musculoskeletal pain (Artus et al., 2017; Valentin et al., 2016). Overall, patients attending NHS 
physiotherapy services appear to have co-existing musculoskeletal pain problems. These patients 
were excluded from the LEAP trial 
Seventy-one (43.8%) patients completed the EQ5D, quality of life questionnaire in this study. On 
average patients were likely, to have a lower EQ5D index score (0.6), than those in the LEAP trial 
(0.7). This difference is in line with the suggested minimally important clinical difference (MCID) 
reported for patients with persistent pain (Corettt & Ruggeri, in press). What is clear is that these 
patients experience significantly worse quality of life, than the population norm for adults between 
the ages of 55-64 in the UK (0.804). This is not the first study to establish that patients with GTPS 
experience poor quality of life, as Fearon et al (2014), reported that patients with GTPS reported 
similar quality of life scores, to those with advanced osteoarthritis of the hip. This study supports 
other data which suggests that lateral hip pain is intrusive, as activities such as walking (65.4%) and 
lying (60.5%) are problematic for the majority of sufferers (Woodley et al, 2008).  
The co-morbidities and medication data recorded in this evaluation, suggests that this diminished 
quality of life may be multi-factorial. 128 subjects suffered 350 medical conditions, including 
cardiovascular complaints (30.2%), digestion problems (19.1%) and metabolic / endocrine disorders 
(17.9%) which have all been linked to tendinopathy (Abate et al, 2013). On top of this, 134 subjects 
were taking 459 prescriptions; and were commonly taking statins (16.7%) and angiotensin 2 blockers 
(11.1%), which have also been linked with the development of tendinopathy and tendon rupture 
(Kirschgesner et al., 2014; Nyyssonen et al., 2018). It is unknown whether these medications 
influence rehabilitative outcomes for GTPS.  
More than one third of subjects (35.2%) were taking opioid medication despite current guidelines 
suggesting these medications should be used judiciously due to side effects and lack of clinical 
efficacy with their long-term usage (Els et al., 2017; NICE, 2019).  
The burden of managing patients with GTPS for the NHS remains unknown. However, this service 
evaluation suggests that they frequently suffer high levels of pain and disability and often have 
symptoms lasting more than 12-months; whilst being on high levels of medication for a range of 
medical conditions. They also frequently undergo radiological imaging (62.3%), despite evidence that 
clinical examination is sufficient (Fearon et al., 2013; Ganderton, Semciw, Cook & Pizzari, 2017; 
Grimaldi et al., 2017) and are treated in a variety of ways including cortico-steroid injections (19.1%), 
despite a lack of proven efficacy (Brinks & Denman, 2011; Rompe et al., 2009). The data in this study 
importantly suggests that patients presenting to physiotherapy services in the NHS with GTPS are 
potentially different in clinically important ways than those recruited to the LEAP trial, and have 
multidimensional needs which may need to be addressed as part of their treatment.  Hence, it is 
unclear whether the findings of the LEAP trial are applicable to patients with GTPS consulting 




This service evaluation relied on data from patient records that is dependent on the thoroughness of 
the documentation of the treating clinician. Methods to select patient records from sites were not 
standardised which could introduce some selection bias. Also, the diagnosis of GTPS was not 
standardised, but previously a large survey of current practice suggests that physiotherapists felt 





Patients presenting to the NHS with GTPS appear to have complex, multi-factorial issues with high 
levels of pain and disability and are often medicated for multiple co-existing conditions. Importantly, 
they have characteristics which differentiate them from patients recruited to the LEAP trial, Hence, it 
is unclear whether the findings of the LEAP trial are applicable to patients with GTPS consulting 





























































Abate, M., Schiavone, C., Salini, V., & Andia, I. (2013). Occurrence of tendon pathologies in metabolic 
disorders. Rheumatology (United Kingdom), 52(4), 599–608. 
https://doi.org/10.1093/rheumatology/kes395 
Albers, I. S., Zwerver, J., Diercks, R. L., Dekker, J. H., & Van Den Akker-Scheek, I. (2016). Incidence and 
prevalence of lower extremity tendinopathy in a Dutch general practice population: A cross 
sectional study. BMC Musculoskeletal Disorders, 17(1). https://doi.org/10.1186/s12891-016-
0885-2 
Artus, M., Campbell, P., Mallen, C. D., Dunn, K. M., & Van Der Windt, D. A. W. (2017). Generic 
prognostic factors for musculoskeletal pain in primary care: A systematic review. BMJ Open, 
7(1), 1–10. https://doi.org/10.1136/bmjopen-2016-012901 
Brinks, A., & Denman, M. (2011). Corticosteroid injections improved shortterm, but not long-term, 
recovery and pain in the greater trochanteric pain syndrome. Annals of Internal Medicine. 
https://doi.org/10.7326/0003-4819-155-8-201110180-02009 
British Medical Association new guide to medicine & drugs (9th ed.). (2015). London: Dorling  
Kindersley. 
 
Coretti S, Ruggeri M, M. P. (in press). What effect size matters? Comparing methods used for 
estimation of the 2 Minimum Clinically Important Difference, 1–25. Retrieved from 
https://editorialexpress.com/cgi-
bin/conference/download.cgi?db_name=SIEP2017&paper_id=82 
Cornally, N., & McCarthy, G. (2011). Chronic Pain: The Help-Seeking Behavior, Attitudes, and Beliefs 
of Older Adults Living in the Community. Pain Management Nursing, 12(4), 206–217. 
https://doi.org/10.1016/j.pmn.2010.12.006 
Demant, A. W., Kocovic, L., Henschkowski, J., Siebenrock, K. A., Ferrari, P., Steinbach, L. S., & 
Anderson, S. E. (2007). Hip pain in renal transplant recipients: Symptomatic gluteus minimus 
and gluteus medius tendon abnormality as an alternative MRI diagnosis to avascular necrosis. 
American Journal of Roentgenology, 188(2), 515–519. https://doi.org/10.2214/AJR.05.1097 
Els, C., Jackson, T. D., Kunyk, D., Lappi, V. G., Sonnenberg, B., Hagtvedt, R., … Straube, S. (2017). 
Adverse events associated with medium- and long-term use of opioids for chronic non-cancer 
pain: an overview of Cochrane Reviews. The Cochrane Database of Systematic Reviews, 10, 
CD012509. https://doi.org/10.1002/14651858.CD012509.pub2 
Fearon,  a. M., Stephens, S., Cook, J. L., Smith, P. N., Cormick, W., & Scarvell, J. M. (2012). Are child 
bearing hips a risk factor for Greater trochanteric pain syndrome? Journal of Bodywork and 
Movement Therapies. https://doi.org/10.1016/j.jbmt.2012.01.060 
Fearon, A. M., Cook, J. L., Scarvell, J. M., Neeman, T., Cormick, W., & Smith, P. N. (2014). Greater 
trochanteric pain syndrome negatively affects work, physical activity and quality of life: a case 
control study. The Journal of Arthroplasty, 29(2), 383–386. 
https://doi.org/10.1016/j.arth.2012.10.016 
Fearon, A. M., Scarvell, J. M., Cook, J. L., & Smith, P. N. F. (2010). Does ultrasound correlate with 
surgical or histologic findings in greater trochanteric pain syndrome? A pilot study. Clinical 
Orthopaedics and Related Research. https://doi.org/10.1007/s11999-009-1174-2 
Fearon, A. M., Scarvell, J. M., Neeman, T., Cook, J. L., Cormick, W., & Smith, P. N. (2013). Greater 
trochanteric pain syndrome: defining the clinical syndrome. British Journal of Sports Medicine, 
47(10), 649–653. https://doi.org/10.1136/bjsports-2012-091565 
Gaida, J. E., Ashe, M. C., Bass, S. L., & Cook, J. L. (2009). Is Adiposity an Under-Recognized Risk Factor  
for Tendinopathy ? A Systematic Review, 61(6), 840–849. https://doi.org/10.1002/art.24518 
 
Ganderton, C., Semciw, A., Cook, J., & Pizzari, T. (2017). Demystifying the Clinical Diagnosis of 
Greater Trochanteric Pain Syndrome in Women. Journal of Women’s Health. 
https://doi.org/10.1089/jwh.2016.5889 
Grimaldi, A., & Fearon, A. (2015). Gluteal Tendinopathy: Integrating Pathomechanics and Clinical 
Features in Its Management. Journal of Orthopaedic & Sports Physical Therapy. 
https://doi.org/10.2519/jospt.2015.5829 
Grimaldi, A., Mellor, R., Nicolson, P., Hodges, P., Bennell, K., & Vicenzino, B. (2017). Utility of clinical 
tests to diagnose MRI-confirmed gluteal tendinopathy in patients presenting with lateral hip 
pain. British Journal of Sports Medicine. https://doi.org/10.1136/bjsports-2016-096175 
Kirchgesner, T., Larbi, A., Omoumi, P., Malghem, J., Zamali, N., Manelfe, J., … Dallaudiere, B. (2014). 
Drug-induced tendinopathy: from physiology to clinical applications. Joint, Bone, Spine : Revue 
Du Rhumatisme, 81(6), 485–492. https://doi.org/10.1016/j.jbspin.2014.03.022 
Lievense, A., Bierma-Zeinstra, S., Schouten, B., Bohnen, A., Verhaar, J., & Koes, B. W. (2005). 
Prognosis of trochanteric pain in primary care. British Journal of General Practice. 
Linton, S. J., & Shaw, W. S. (2011). Impact of Psychological Factors in the Experience of Pain. Physical 
Therapy, 91(5), 700–711. https://doi.org/10.2522/ptj.20100330 
Long, S. S., Surrey, D. E., & Nazarian, L. N. (2013). Sonography of greater trochanteric pain syndrome 
and the rarity of primary bursitis. American Journal of Roentgenology. 
https://doi.org/10.2214/AJR.12.10038 
Longo, U. G., Rittweger, J., Garau, G., Radonic, B., Gutwasser, C., Gilliver, S. F., … Zielin, J. (2009). No 
Influence of Age , Gender , Weight , Height , and Impact Profile in Achilles Tendinopathy in 
Masters Track and Field Athletes, 1400–1405. https://doi.org/10.1177/0363546509332250 
Maffulli, N., & Kader, D. (2002). Tendinopathy of tendo achillis. The Journal of Bone and Joint 
Surgery. British Volume, 84(1), 1–8. 
Mellor, R., Bennell, K., Grimaldi, A., Nicolson, P., Kasza, J., Hodges, P., … Vicenzino, B. (2018). 
Education plus exercise versus corticosteroid injection use versus a wait and see approach on 
global outcome and pain from gluteal tendinopathy: prospective, single blinded, randomised 
clinical trial. The Bmj BMJ, 361. https://doi.org/10.1136/bmj.k1662 
Mellor, R., Grimaldi, A., Wajswelner, H., Hodges, P., Abbott, J. H., Bennell, K., & Vicenzino, B. (2016). 
Exercise and load modification versus corticosteroid injection versus ‘wait and see’ for 
persistent gluteus medius/minimus tendinopathy (the LEAP trial): a protocol for a randomised 
clinical trial. BMC Musculoskeletal Disorders. https://doi.org/10.1186/s12891-016-1043-6 
NHS Health Research Authority . Defining research. London: NHS Health Research Authority (2016), 
http://www.hra.nhs.uk/documents/2016/06/defining-research.pdf (accessed 18th June 2019). 
NICE Guidelines (2019). World Health Organisation. Medicines optimisation in chronic pain, (January 
2017), 1–10. 
 
Nyyssonen, T., Lantto, I., Luthje, P., Selander, T., & Kroger, H. (2018). Drug treatments associated 
with Achilles tendon rupture. A case-control study involving 1118 Achilles tendon ruptures. 
Scandinavian Journal of Medicine & Science in Sports, 28(12), 2625–2629. 
https://doi.org/10.1111/sms.13281 
Rompe, J. D., Segal, N. A., Cacchio, A., Furia, J. P., Morral, A., & Maffulli, N. (2009). Home training, 
local corticosteroid injection, or radial shock wave therapy for greater trochanter pain 
syndrome. American Journal of Sports Medicine, 37(10), 1981–1990. 
https://doi.org/10.1177/0363546509334374 
Scott, A., Zwerver, J., Grewal, N., de Sa, A., Alktebi, T., Granville, D. J., & Hart, D. A. (2015). Lipids, 
adiposity and tendinopathy: is there a mechanistic link? Critical review. British Journal of Sports 
Medicine, 49(15), 984–988. https://doi.org/10.1136/bjsports-2014-093989 
Segal, N. A., Felson, D. T., Torner, J. C., Zhu, Y., Curtis, J. R., Niu, J., & Nevitt, M. C. (2007). Greater 
Trochanteric Pain Syndrome: Epidemiology and Associated Factors. Archives of Physical 
Medicine and Rehabilitation. https://doi.org/10.1016/j.apmr.2007.04.014 
Stephens, G., O’Neill, S., French, H. P., Fearon, A., Grimaldi, A., O’Connor, L., … Littlewood, C. (2019). 
A survey of physiotherapy practice (2018) in the United Kingdom for patients with greater 
trochanteric pain syndrome. Musculoskeletal Science and Practice, 40(September 2018), 10–20. 
https://doi.org/10.1016/j.msksp.2019.01.004 
Tan, L. A., Benkli, B., Tuchman, A., Li, X. J., Desai, N. N., Bottiglieri, T. S., … Lehman, R. A. J. (2018). 
High prevalence of greater trochanteric pain syndrome among patients presenting to spine 
clinic for evaluation of degenerative lumbar pathologies. Journal of Clinical Neuroscience : 
Official Journal of the Neurosurgical Society  of Australasia, 53, 89–91. 
https://doi.org/10.1016/j.jocn.2018.04.030 
Thompson, A. E., Anisimowicz, Y., Miedema, B., Hogg, W., Wodchis, W. P., & Aubrey-Bassler, K. 
(2016). The influence of gender and other patient characteristics on health care-seeking 
behaviour: A QUALICOPC study. BMC Family Practice, 17(1), 1–7. 
https://doi.org/10.1186/s12875-016-0440-0 
Tortolani, P. J., Carbone, J. J., & Quartararo, L. G. (2002). Greater trochanteric pain syndrome in 
patients referred to orthopedic spine specialists. The Spine Journal : Official Journal of the 
North American Spine Society, 2(4), 251–254. 
Valentin, G. H., Pilegaard, M. S., Vaegter, H. B., Rosendal, M., Ørtenblad, L., Væggemose, U., & 
Christensen, R. (2016). Prognostic factors for disability and sick leave in patients with subacute 
non-malignant pain: a systematic review of cohort studies. BMJ Open, 6(1), e007616. 
https://doi.org/10.1136/bmjopen-2015-007616 
Vardeh, D., Mannion, R. J., Woolf, C. J., Hospital, W., Rd, H., & Children, B. (2017). Towards a 
mechanism-based approach to pain diagnosis, 17, 1–36. 
https://doi.org/10.1016/j.jpain.2016.03.001. 
Woodley, S. J., Nicholson, H. D., Livingstone, V., Doyle, T. C., Meikle, G. R., Macintosh, J. E., & Mercer, 
S. R. (2008). Lateral Hip Pain: Findings From Magnetic Resonance Imaging and Clinical 
Examination. Journal of Orthopaedic & Sports Physical Therapy, 38(6), 313–328. 
https://doi.org/10.2519/jospt.2008.2685 
 
World Health Organisation (2018). International Classification of Diseases 11th Revision. Retrieved       
         from  https://icd.who.int/en/ (Accessed 18th June 2019) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
